var data={"title":"Golimumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Golimumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/381550?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=golimumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Golimumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764598\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infection:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients treated with golimumab are at an increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue golimumab if a patient develops a serious infection.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Reported infections with tumor necrosis factor (TNF) blockers include the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before golimumab use and during therapy. Initiate treatment for latent infection prior to golimumab use.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk of invasive fungal infections who develop severe systemic illness.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Consider the risks and benefits of treatment prior to initiating therapy in patients with chronic or recurrent infection.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients closely for the development of signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7710508\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Simponi;</li>\n      <li>Simponi Aria</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10165746\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Simponi;</li>\n      <li>Simponi IV</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7714309\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antipsoriatic Agent;</li>\n      <li>\n        Antirheumatic, Disease Modifying;</li>\n      <li>\n        Monoclonal Antibody;</li>\n      <li>\n        Tumor Necrosis Factor (TNF) Blocking Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764854\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Corticosteroids, <i>nonbiologic</i> disease-modifying antirheumatic drugs (DMARDs), and/or NSAIDs may be continued for the treatment of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Golimumab should not be used in combination with <i>biologic</i> DMARDs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter (either alone or in combination with methotrexate or other nonbiologic DMARDs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 50 mg once a month (either alone or in combination with methotrexate or other nonbiologic DMARDs)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter (either alone or in combination with methotrexate or other nonbiologic DMARDs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 50 mg once a month (either alone or in combination with methotrexate or other nonbiologic DMARDs)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter (in combination with methotrexate)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 50 mg once a month (in combination with methotrexate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis: </b>SubQ: Induction: 200 mg at week 0, then 100 mg at week 2, followed by maintenance therapy of 100 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Axial spondyloarthritis (active, nonradiographic) (off-label use): </b>SubQ: 50 mg once every 4 weeks for 16 weeks (Sieper 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990972\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988341\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764855\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764860\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Simponi Aria: 50 mg/4 mL (4 mL) [latex free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Simponi: 50 mg/0.5 mL (0.5 mL); 100 mg/mL (1 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Simponi: 50 mg/0.5 mL (0.5 mL); 100 mg/mL (1 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764600\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874784\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Simponi: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125289s139lbl.pdf#page=38&amp;token=3clO6Osbt1QeL4KjGpkgpBTH3TaqV8ofq84suH9Kn9xDYEXqd9LJBjpAIOvA9LGLc5Z+ILDKNeKXGTkNO0d4n207K4enF7q7rjxSxMzP5Jzv4RgXGkMDQuf2qwZfGnFC&amp;TOPIC_ID=9086\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125289s139lbl.pdf#page=38</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Simponi Aria: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125433s020s021lbl.pdf#page=32&amp;token=tC66636W7G+8COmyoHJXKuV3GxD+8zoHdwXRKaXH6shRLLtNv6vzO0Q7FBEQzsBQPRGnpRqnpMg0EXM7oXtCn/6k2wYTbvu7W/24iWB2qv6nZbqGOL0h5fXqvZ4KO3NV&amp;TOPIC_ID=9086\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125433s020s021lbl.pdf#page=32</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764856\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> The safety and efficacy of switching between the IV and SubQ formulations and routes have not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Dilute prior to use. Infuse over 30 minutes, using an infusion set with an in-line low protein-binding 0.22 micron filter. Do not infuse in the same line with other medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subcutaneous injection: Hold autoinjector firmly against skin and inject subcutaneously into thigh, lower abdomen (below navel), or upper arm.  A loud click is heard when injection has begun. Continue to hold autoinjector against skin until second click is heard (may take 3 to 15 seconds). Following second click, lift autoinjector from injection site. Rotate injection sites and avoid injecting into tender, red, scaly, hard, or bruised skin, or areas with scars or stretch marks. If multiple injections are required for a single dose, administer at different sites on body.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7714311\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis </b>(Simponi, Simponi Aria): Treatment of adults with active ankylosing spondylitis (alone or in combination with methotrexate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis</b> (Simponi, Simponi Aria): Treatment of adults with active psoriatic arthritis (alone or in combination with methotrexate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis</b> (Simponi, Simponi Aria): Treatment of adults with moderately-to-severely active rheumatoid arthritis (in combination with methotrexate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis</b> (Simponi): Treatment of adults with moderately-to-severely active ulcerative colitis in patients with corticosteroid dependence or who are refractory or intolerant to oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine (to induce and maintain clinical response, improve mucosal appearance during induction, induce clinical remission, and achieve and sustain remission in induction responders)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50324911\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Axial spondyloarthritis (active, nonradiographic)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50169189\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Golimumab may be confused with sarilumab.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764750\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Positive ANA titer (intravenous: 17%, newly positive; subcutaneous: 4%, titer &ge;1:160)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (intravenous: 19% to 21%, drug-tolerant EIA method; intravenous: 3%, neutralizing; anti-dsDNA: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (27% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (13% to 16%; includes laryngitis, pharyngitis, and rhinitis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;2%), paresthesia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased neutrophils (&le;5%), leukopenia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&le;8%; &ge;3 x ULN to &lt;5 x ULN: 3%; &ge;5 x ULN: &le;2%), increased serum AST (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (4% to 5%; includes herpes and influenza), fungal infection (&le;2%; may be invasive or superficial), bacterial infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (subcutaneous: 3% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (&le;6%), bronchitis (2% to 3%), sinusitis (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2%), infusion-related reaction (intravenous: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Cellulitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Tuberculosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abscess, agranulocytosis, anaphylaxis, aplastic anemia, atypical serious infection, bullous skin disease, cardiac failure, demyelinating disease of the central nervous system, dyspnea, exfoliation of skin, Guillain-Barre syndrome, hepatitis B, hepatotoxicity (idiosyncratic), hypersensitivity, hypersensitivity angiitis, infective bursitis, interstitial pulmonary disease, leukemia, lupus-like syndrome, malignant lymphoma, malignant melanoma, malignant neoplasm, Merkel cell carcinoma, multiple sclerosis, mycobacterial infection, nausea, neutropenia, non-Hodgkin lymphoma, optic neuritis, pancytopenia, peripheral demyelinating polyneuropathy, pneumonia, pruritus, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pyelonephritis, sarcoidosis, septic arthritis, septic shock, thrombocytopenia, urticaria, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764747\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to golimumab, latex, or any other component of formulation or packaging; patients with severe infections (eg, sepsis, tuberculosis, opportunistic infections); moderate or severe heart failure (NYHA class III/IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764748\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Demyelinating disease: Rare cases of new-onset or exacerbation of demyelinating disorders (eg, multiple sclerosis, optic neuritis, Guillain-Barr&eacute; syndrome, polyneuropathy) have been reported. Consider discontinuing in patients who develop peripheral or CNS demyelinating disorders during treatment. Use with caution in patients with pre-existing or recent onset central or peripheral nervous system demyelinating disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Worsening and new-onset heart failure (HF) (some fatal) have been reported with golimumab and other TNF-blockers. Monitor closely and discontinue with onset or worsening of symptoms. Use with caution in patients with HF or decreased left ventricular function. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Cases of pancytopenia and other significant cytopenias, including aplastic anemia, have been reported with TNF-blocking agents. Pancytopenia, leukopenia, neutropenia, and thrombocytopenia have occurred with golimumab. Consider discontinuing with significant hematologic abnormalities. Use with caution in patients with underlying hematologic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: Rare reactivation of hepatitis B virus (HBV), sometimes fatal, has occurred in chronic virus carriers, usually in patients receiving concomitant immunosuppressants; evaluate for HBV prior to initiation in all patients. Patients who test positive for HBV surface antigen should be referred for hepatitis B evaluation/treatment prior to golimumab initiation. Monitor for clinical and laboratory signs of active infection during and for several months following discontinuation of golimumab treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe systemic hypersensitivity reactions (including anaphylaxis) have been reported (some have occurred with the first dose) following intravenous and subcutaneous administration. Symptoms associated with reactions may include dyspnea, hives, nausea, and pruritus; reactions occurred during and within 1 hour of the start of IV infusion. Discontinue immediately if signs develop and initiate appropriate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Patients receiving golimumab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids). Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral, or other opportunistic infections (including legionellosis and listeriosis) have been reported in patients receiving TNF-blocking agents, including golimumab. May present as disseminated (rather than local) disease. Histoplasmosis testing (antigen or antibody) may be negative in some patients with active infection. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.</b> Caution should be exercised (consider risks versus benefits) when considering use in the elderly, patients taking concomitant immunosuppressants, patients with chronic or recurrent infection, patients who have been exposed to tuberculosis, patients with a history of opportunistic infection, patients with comorbid conditions that predispose them to infections (eg, diabetes), or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis). Do not initiate golimumab therapy in patients with active infection, including localized infection, which is clinically important. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescent patients receiving TNF-blocking agents.</b> Half of the malignancies reported in children were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included malignancies not typically observed in this population. The onset of malignancy was after a median of 30 months (range: 1 to 84 months) after the initiation of the TNF-blocking agent; most patients were receiving concomitant immunosuppressants. The impact of golimumab on the development and course of malignancy is not fully defined. Compared with the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Lymphomas and other malignancies were also observed (at rates higher than expected for the general population) in adult patients receiving TNF-blocking agents. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn disease or ulcerative colitis treated with a TNF-blocking agent and concurrent or prior azathioprine or mercaptopurine. Melanoma and Merkel cell carcinoma have been reported in patients receiving TNF-blocking agents including golimumab. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk for skin cancer. Consider risks versus benefits in patients with a known malignancy (other than a successfully treated nonmelanoma skin cancer) and if considering continuing treatment in a patient who develops a malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis:<b> [US Boxed Warning]: Tuberculosis (disseminated or extrapulmonary) has been reported in patients receiving golimumab; both reactivation of latent infection and new infections have been reported. Patients should be evaluated for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to and during therapy. Treatment of latent tuberculosis should be initiated before use. Monitor for development of tuberculosis throughout treatment in patients with initial negative tuberculin skin tests,</b> patients currently receiving treatment for latent tuberculosis, or patients previously treated for tuberculosis; active tuberculosis has developed in this population during treatment with TNF-blocking agents. Use with caution in patients who have resided in regions where tuberculosis is endemic. Consider antituberculosis therapy if an adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or for patients with risk factors despite negative skin test. Prior to use, consider risks versus benefits in patients who have been exposed to tuberculosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; general incidence of infection is higher in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescent patients receiving TNF-blocking agents. </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage form specific issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Some dosage forms may contain dry natural rubber (latex).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration formulation/route: The safety and efficacy of switching between the IV and SubQ formulations and routes have not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of infection by live vaccines in patients receiving therapy. In clinical trials, humoral response to pneumococcal vaccine was not suppressed in psoriatic arthritis patients receiving golimumab.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299418\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734106\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9086&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">InFLIXimab: Golimumab may enhance the immunosuppressive effect of InFLIXimab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764743\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Information related to the use of golimumab in pregnancy is limited (Bazzani 2015; Weber-Schoendorfer 2015). Monoclonal antibodies cross the placenta during the third trimester. Based on data from other TNF-blockers, antibodies may be present in the newborn serum for up to 6 months and infants exposed to golimumab in utero may be at risk of increased infection. Administration of live vaccines to newborns is not recommended until 6 months after the last maternal dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764746\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if golimumab is present in breast milk. Maternal IgG is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764858\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential; latent TB screening (prior to initiating and periodically during therapy); HBV screening (prior to initiating [all patients]; during and for several months following therapy [HBV carriers]); monitor improvement of symptoms and physical function assessments; signs/symptoms of infection (prior to, during, and following therapy); signs/symptoms/worsening of heart failure signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) including periodic skin examination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764845\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Human monoclonal antibody that binds to human tumor necrosis factor alpha (TNF&alpha;), thereby interfering with endogenous TNF&alpha; activity. Biological activities of TNF&alpha; include the induction of proinflammatory cytokines (interleukin [IL]-6, IL-8, Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor), expression of adhesion molecules (E-selectin, vascular cell adhesion molecule [VCAM]-1, intercellular adhesion molecule [ICAM]-1) necessary for leukocyte infiltration, activation of neutrophils and eosinophils.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7764847\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 151 &plusmn; 61 mL/kg (distributed primarily to circulatory system with limited extravascular distribution) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: ~53%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Pathway unknown</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: SubQ: 2-6 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196150\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight: Following IV administration, patients with higher body weights tend to have higher serum golimumab concentrations (compared to lower body weights).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321953\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Simponi Aria Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/4 mL (4 mL): $2,080.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Simponi Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/0.5 mL (0.5 mL): $5,423.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $6,237.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Simponi Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/0.5 mL (0.5 mL): $5,423.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $6,237.29</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961950\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Simponi (AE, AR, AT, AU, BB, BE, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GR, GT, HK, HN, HR, IE, IL, IS, JP, KR, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, VN);</li>\n      <li>Simponi IV (HK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bazzani C, Scrivo R, Andreoli L, et al. Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. <i>Clin Exp Rheumatol</i>. 2015;33(5):688-693.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/26311348/pubmed\" target=\"_blank\" id=\"26311348\">26311348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Braun J, Baraliakos X, Hermann KG, et al, &ldquo;Golimumab Reduces Spinal Inflammation in Ankylosing Spondylitis: MRI Results of the Randomised, Placebo- Controlled GO-RAISE Study,&rdquo; <i>Ann Rheum Dis</i>, 2012, 71(6):878-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/22128083/pubmed\" target=\"_blank\" id=\"22128083\">22128083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Genovese MC, Han C, Keystone EC, et al, &ldquo;Effect of Golimumab on Patient-Reported Outcomes in Rheumatoid Arthritis: Results From the GO-FORWARD Study,&rdquo; <i>J Rheumatol</i>, 2012, 39(6):1185-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/22505702/pubmed\" target=\"_blank\" id=\"22505702\">22505702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inman RD, Davis JC Jr, van der Heijde D, et al, &ldquo;Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis, Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial,&rdquo; <i>Arthritis Rheum</i>, 2008, 58(11):3402-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/18975305/pubmed\" target=\"_blank\" id=\"18975305\">18975305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kavanaugh A, Mcinnes I, Mease P, et al, &ldquo;Golimumab, a New Human Tumor Necrosis Factor &alpha; Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis, Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study,&rdquo; <i>Arthritis Rheum</i>, 2009, 60(4):976-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/19333944/pubmed\" target=\"_blank\" id=\"19333944\">19333944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kay J, Matteson EL, Dasgupta B, et al, &ldquo;Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate, A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study,&rdquo; <i>Arthritis Rheum</i>, 2008, 58(4):964-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/18383539/pubmed\" target=\"_blank\" id=\"18383539\">18383539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keystone EC, Genovese MC, Klareskog L, et al, &ldquo;Golimumab, a Human Antibody to TNF- &alpha; Given by Monthly Subcutaneous Injections, in Active Rheumatoid Arthritis Despite Methotrexate: The GO-FORWARD Study,&rdquo; <i>Ann Rheum Dis,</i>, 2009, 68(6):789-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/19066176/pubmed\" target=\"_blank\" id=\"19066176\">19066176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo; <i>JAMA</i>, 2012, 308(9): 898-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/22948700/pubmed\" target=\"_blank\" id=\"22948700\">22948700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26139307\"></a>Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. <i>Arthritis Rheumatol</i>. 2015;67(10):2702-2712. doi: 10.1002/art.39257.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/26139307/pubmed\" target=\"_blank\" id=\"26139307\">26139307</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simponi (golimumab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simponi (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simponi Aria (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simponi IV (golimumab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(5):625-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/22473917/pubmed\" target=\"_blank\" id=\"22473917\">22473917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-&alpha; inhibitor therapy during the first trimester: a prospective multicentre cohort study. <i>Br J Clin Pharmacol</i>. 2015;80(4):727-739.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/25808588/pubmed\" target=\"_blank\" id=\"25808588\">25808588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, et al, &ldquo;Intravenous Golimumab is Effective in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy With Responses as Early as Week 2: Results of the Phase 3, Randomised, Multicentre, Double-Blind, Placebo-Controlled GO-FURTHER Trial,&rdquo; <i>Ann Rheum Dis</i>, 2013, 72(3):381-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/golimumab-drug-information/abstract-text/22661646/pubmed\" target=\"_blank\" id=\"22661646\">22661646</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9086 Version 171.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7764598\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7710508\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10165746\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7714309\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7764854\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990972\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988341\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7764855\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7764860\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7764600\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874784\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7764856\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7714311\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50324911\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50169189\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7764750\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7764747\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7764748\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299418\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7734106\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7764743\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7764746\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7764858\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7764845\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7764847\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196150\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321953\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961950\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9086|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=golimumab-patient-drug-information\" class=\"drug drug_patient\">Golimumab: Patient drug information</a></li></ul></div></div>","javascript":null}